Galectin‑3 in patients with left ventricular hypertrophy and metabolic syndrome

Objective. To investigate the serum levels of galectin‑3 in patients with metabolic syndrome (MS) and in patients with combination of MS and left ventricular hypertrophy (LVH), as well as to define the role of this marker of fibrosis in MS.Design and methods. The study included 43 patients with MS (33 patients had LVH), and 33 patients of comparable age without MS (LVH was diagnosed in 10). The level of serum galectin‑3 was determined by enzyme immunoassay kits Platinum ELISA.Results. The average level of galectin‑3 in the MS group was significantly higher (1,89 ± 1,71 ng/ml), compared to the group without MS (1,03 ± 0,22 ng/ml, p = 0,006). The study showed a positive correlation between the level of galectin‑3 and LVH (r = 0,323, p = 0,004). The mean value of galectin‑3 in patients with no evidence of LVH was 1,2 ± 0,76 ng/ml, in patients with LVH — 2,1 ± 2,02 ng/ml.Conclusions. In patients with MS the level of galectin‑3 was higher than in patients without MS, and in patients with MS and concomitant LVH it was higher than in patients without LVH. In patients with MS and LVH increased galectin‑3 levels may indicate the severity of myocardial fibrosis and help for prognosis evaluation.

Download Full-text

THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME

Rational Pharmacotherapy in Cardiology ◽

10.20996/1819-6446-2014-10-1-37-42 ◽

2014 ◽

Vol 10 (1) ◽

pp. 37-42 ◽

Cited By ~ 1

Author(s):

A. N. Zakirova ◽

E. Z. Fatkullina ◽

N. E. Zakirova

Keyword(s):

Metabolic Syndrome ◽

Matrix Metalloproteinases ◽

Left Ventricular Hypertrophy ◽

Arterial Hypertension ◽

Ventricular Hypertrophy ◽

Left Ventricular ◽

The Matrix

Download Full-text

P0953NITRIC OXIDE AND LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH CHRONIC RENAL FAILURE

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfaa142.p0953 ◽

2020 ◽

Vol 35 (Supplement_3) ◽

Author(s):

Leila Azouaou ◽

Khelfi Abderrezak ◽

Bellouti Wafa ◽

Medina Arab

Keyword(s):

Nitric Oxide ◽

Renal Failure ◽

Chronic Renal Failure ◽

Left Ventricular Hypertrophy ◽

Ventricular Hypertrophy ◽

Mean Value ◽

Left Ventricular ◽

The Body ◽

Cardiac Complications ◽

The Mean

Abstract Background and Aims Nitric oxide, nitric oxide, nitric oxide or NO is an endogenous molecule released by endothelial cells, macrophages, liver cells and neurons. There are three forms of nitric oxide synthase in the body. : the inducible form (iNO), the neuronal form and the endothelial form (eNO). In this work we are interested in (iNO) in patients with CKD and their impact on cardiac complications. Method A study of 202 patients with chronic renal failure at different stages (2.3.4.5 and 5D) was performed in our department. We investigated the correlation between mean (iNO) values in patients with CKD and its relationship with left ventricular hypertrophy. Results The mean age of the patients is 56.5 ± 17 years with a sex ratio of 1.43. The mean value of (iNO) is 65.82 ± 1.06 μmol / l. Its value increases significantly with the degradation of renal function (p <0.05) (stage 2 (61.75 ± 2.34), stage 3 (63.91 ± 2.21). ), stage 4 (64.08 ± 2.18), stage 5 (67 ± 2.7) and stage 5D (72.47 ± 2.18μmol / l). It is found that the mean value of nitric oxide NO is slightly higher in patients with HVG + ( 67.58 ± 1.48) versus HVG-patients (63.1 ± 1.39) (p <0.05).Discussion: iNOS secreted nitric oxide (NO) initiates cardiac remodeling to lead to left ventricular hypertrophy and cardiac fibrosis Conclusion Cardiac complications are the leading cause of death in patients with chronic renal failure. oxidative stress is a risk factor for these cardiac complications, iNOS accelerates cardiac aging.

Download Full-text